awmsg logo



adalimumab (Humira®)


Reference No. 3371

Publication date:
08/08/2017


Appraisal information

adalimumab (Humira®) 40 mg/0.8 ml solution for injection


Company: AbbVie Ltd
BNF category: Skin
NMG meeting date: 07/06/2017
AWMSG meeting date: 19/07/2017
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1217
Ministerial ratification: 07/08/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic hidradenitis suppurativa (HS) therapy. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent to or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download